« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?

  • Raju Kumar Mandal, M.Sc.

      Affiliations

    • RKM thanks the Council of Scientific and Industrial Research, New Delhi, India for providing Junior Research fellowship during the course of study.
    • ,
  • Rama Devi Mittal, Ph.D.

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +091-522-2668004-8 ext. 4116; fax: +091-522-2668-017.

Received 8 April 2010 ,Revised 11 May 2010 ,Accepted 13 May 2010. Published online 07 September 2010 Corrected Proof

References 

  1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–67
  2. Sinha R, Anderson DE, McDonald SS, et al. Cancer risk and diet in India. J Postgrad Med. 2003;49:222–228
  3. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85
  4. Wagner U, Suess K, Luginbuhl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 1999;188:44–50
  5. Wang LE, Cheng L, Spitz MR, et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003;42:1–8
  6. Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299
  7. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602
  8. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 2001;14:428–436
  9. Sherr CJ. Cancer cell cycles. Science (New York). 1996;274:1672–1677
  10. Kibel AS, Isaacs WB. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology. 2000;55:316–322
  11. Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011
  12. Driver KE, Song H, Lesueur F, et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis. 2008;29:333–341
  13. Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103:116–120
  14. Liu B, Zhang Y, Jin M, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010;49:75–84
  15. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34:577–582
  16. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic Lupus erythematosus. J Rheumatol. 2002;29:1183–1188
  17. Sibley K, Rollinson S, Allan JM, et al. Functional Fas promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–4330
  18. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58
  19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
  20. Lum SS, Chua HW, Li H, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 2008;29:754–761
  21. Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–734
  22. Li C, Wu W, Liu J, et al. Functional polymorphisms in the promoter regions of the Fas and Fas ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics. 2006;16:245–251
  23. Hu Z, Jin G, Wang L, et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 2007;16:2717–2723
  24. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 2001;14:428–436
  25. Stoehr R, Hitzenbichler F, Kneitz B, et al. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer. 2008;99:78–82
  26. Singh V, Rastogi N, Mathur N, et al. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. AEP. 2008;18:48–57
  27. Kang S, Wang DJ, Li WS, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–577
  28. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Can Res. 2005;65:9582–9587
  29. Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103:116–120
  30. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234:364–368
  31. Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011
  32. Wang M, Wu D, Tan M, et al. Fas and Fas ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet. 2009;47:559–568

☆ This study was supported by Uttar Pradesh Council of Science and Technology (UPCST) grant, Lucknow, India.

PII: S1078-1439(10)00130-4

doi: 10.1016/j.urolonc.2010.05.006

« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Article Tools